Asset and Financial Position of the Bayer Group

Asset and Capital Structure

Bayer Group Summary Statements of Financial Position

 

 

Dec. 31, 2017

 

March 31, 2018

 

Change

 

 

€ million

 

€ million

 

%

Noncurrent assets

 

45,014

 

42,225

 

−6.2

Assets held for sale

 

2,081

 

3,132

 

+50.5

Other current assets

 

27,992

 

30,037

 

+7.3

Current assets

 

30,073

 

33,169

 

+10.3

Total assets

 

75,087

 

75,394

 

+0.4

Equity

 

36,861

 

38,384

 

+4.1

Noncurrent liabilities

 

24,633

 

23,912

 

−2.9

Liabilities directly related to assets held for sale

 

111

 

520

 

.

Other current liabilities

 

13,482

 

12,578

 

−6.7

Current liabilities

 

13,593

 

13,098

 

−3.6

Liabilities

 

38,226

 

37,010

 

−3.2

Total equity and liabilities

 

75,087

 

75,394

 

+0.4

  • Between December 31, 2017, and March 31, 2018, total assets increased by €0.3 billion to €75.4 billion.
  • Noncurrent assets decreased by €2.8 billion to €42.2 billion. Investments accounted for using the equity method declined by €1.4 billion, largely through the sale of further Covestro shares. Total current assets increased by €3.1 billion to €33.2 billion. The assets held for sale in connection with the planned acquisition of Monsanto increased by €1.1 billion, due particularly to the planned sale of the vegetable seeds business.
  • Equity rose by €1.5 billion compared with December 31, 2017, to €38.4 billion. The income after income taxes of €2.0 billion had a positive effect. Currency effects recognized outside profit and loss reduced equity by €0.4 billion. A decline of €0.2 billion came from the increase in pension provisions outside profit or loss. The equity ratio increased to 50.9% as of March 31, 2018 (March 31, 2017: 49.1%).
  • Liabilities as of March 31, 2018, decreased by €1.2 billion to €37.0 billion.
Compare to Last Year